AUDDIA INC. (AUUD): Nasdaq/NYSE listing notice — Auddia receives Nasdaq delisting notice for bid price non-compliance; plans to appeal

AUDDIA INC.

Nasdaq staff determined to delist AUUD for failing to regain $1.00 minimum bid price compliance.
Company ineligible for additional 180-day cure period; notice received October 24, 2023.
Auddia intends to request a hearing before a Nasdaq Hearings Panel to appeal the determination.
Trading will remain on Nasdaq pending the hearing process and the Panel's written decision.
Initial non-compliance notice was April 24, 2023; the 180-day cure period expired October 23, 2023.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

AUDDIA INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

October 24, 2023, the Company received a written notice from the Nasdaq staff indicating that the Company had not regained compliance with the Bid Price Requirement and was not eligible for the additional 180 calendar day compliance period. As a result, the Staff determined to delist the Company’s Common Stock from Nasdaq, unless the Company timely requests an appeal of the Staff’s determination to a Hearings Panel (the “Panel”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. The Company intends to request a hearing before the Panel to appeal the October notice an

View on SEC.gov

6 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

AUDDIA INC. filing history →

Source: SEC EDGAR

accession 0001683168-23-007504

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.